The Tool That Proved Startups Need Diagnosis

At a Glance

In 2011, the Startup Genome Project built a diagnostic tool that 34,000 founders used. It proved startup self-assessment works.
The tool was acquired and killed. The research continued as Startup Genome. The diagnostic capability was never replaced.
The gap it identified in 2011 still exists in 2026. No tool connects holistic business diagnosis to actionable guidance.
Sova picks up where Startup Compass left off, but goes further: not just where you stand, but what to do about it.

The Research That Started It All

In 2011, the Startup Genome Project, founded by Bjoern Lasse Herrmann, Max Marmer, and Ertan Dogrultan, and supported by faculty from Berkeley and Stanford, analysed over 3,200 high-growth technology startups to answer a deceptively simple question: why do most startups fail?

Their finding was striking. 74% of high-growth internet startup failures are caused by premature scaling. Not competition, not bad luck, not lack of funding. Founders destroying their own companies by doing the right things at the wrong time.

They found that every startup moves through developmental stages: Discovery, Validation, Efficiency, Scale. And that failure happens when founders scale one area of the business before completing foundational work in another. Hiring a sales team before validating product-market fit. Raising capital before understanding unit economics. Building infrastructure before confirming anyone wants the product.

The data was clear: startups that scaled consistently across all dimensions grew 20 times faster than those that didn't.

They Built a Tool to Fix It

Off the back of this research, the team built Startup Compass: a free benchmarking tool that let founders assess their startup's health across 25 key performance indicators. You connected your analytics, CRM, and payment tools, and the system told you not just how your business was performing, but whether your pattern of performance matched startups that succeed or startups that fail.

It was a startup doctor. 34,000 companies signed up. The research was widely adopted across universities globally. Steve Blank, the godfather of the lean startup movement, gave the research an "A+" on his blog, writing that the team had "gone a long way to turn hypotheses about early-stage Internet startups into facts."

For the first time, founders had a structured, evidence-based way to diagnose their own business, instead of guessing.

Then It Was Killed

In late 2013, Startup Compass relaunched with $700,000 in angel funding. By October 2014, the company had raised $3 million and rebranded as Compass.co. Then, in June 2016, Compass pivoted away from startup benchmarking entirely, deciding that e-commerce analytics for small businesses was a "far more underserved market." In March 2017, Sage Group acquired the company for its analytics technology. The startup diagnostic tool was discontinued.

It wasn't a failure of the product. 34,000 companies had validated the demand. It was a failure of business model. The tool showed founders where they stood, but it didn't tell them what to do next. Benchmarking without guidance turned out to be hard to monetise. The company chased a different market, got acquired, and the diagnostic capability was shelved.

Meanwhile, the research arm continued as Startup Genome. Today, it works with over 160 government and economic development agencies across 55 countries, publishing the annual Global Startup Ecosystem Report. Their latest, GSER 2025, analyses 350+ ecosystems across 5 million startups. It ranks cities like Sydney (#25 globally) and Melbourne (#32, up eight ranks over five years). It is excellent, rigorous research.

But it is written for policymakers and economic development agencies. It does nothing for the individual founder sitting in a co-working space trying to work out whether to hire their first employee or fix their business model first.

The most research-backed startup diagnostic tool ever built was abandoned. Not because the idea was wrong, but because the company behind it chose a different path.

Nobody Picked Up the Baton

What surprised me most when I dug into this history was what came after: almost nothing.

The space that Compass left behind has fragmented into narrow, single-dimension tools. The Founder Institute offers a psychology-based entrepreneurial trait assessment. ReadyScore.ai rates investor readiness. ICONIQ provides SaaS metrics benchmarking for funded companies. The ITC offers a UN-backed diagnostic for SMEs in developing economies.

But none of them do what Compass did: give founders a holistic, structured view of their entire business health. And none of them connect that diagnosis to action. The gap Compass identified in 2011 still exists in 2026.

The Evidence Keeps Building

I didn't know any of this when I started building Sova. I came at it from 15 years of strategy and transformation work, applying business excellence frameworks like Baldrige, EFQM and ISO 9001 to large organisations, and asking why startups couldn't access the same tools.

But what struck me, once I found the Startup Genome research, was how much subsequent evidence supports the same conclusion:

CB Insights (2021) analysed 111 startup post-mortems and found 38% failed from running out of cash, 35% from no market need, and 20% from being outcompeted
Frontiers in Psychology (2024) identified "information-seeking" and "customer service orientation" as the two most prominent competency deficits in failed startups
GSER 2025 identified a "shortage of scale-up experience" in Australian ecosystems, with most support skewed to early-stage startups and limited guidance once founders achieve traction

The pattern is the same across every major study. Founders fail because they don't know what they don't know, and they lack a structured way to find out.

What Sova Does Differently

Finding this history validated something I'd already built, but it also sharpened what makes Sova different. Compass told you where you stood. Sova tells you what to do about it.

	Startup Compass	Sova
What it asks	25 KPIs pulled from analytics and payment tools	9 interconnected business elements, stage-gated to prevent premature scaling
What you get back	"You're behind peers on churn rate"	"Your customer retention is underdeveloped at Validation stage. Here's why 35% of startups fail from this, and three proven frameworks to fix it"
What to do next	"Good luck"	"Start with Cohort Analysis, then apply the LTV:CAC framework. Here's a step-by-step guide from HBR"
Where to get help	Not provided	"Based on your stage and location, here are 12 programs in Victoria that can help, including two with open grant rounds"
Ongoing guidance	None	"Ask me anything about your results." AI advisor trained on the same research, contextualised to your assessment
Who it serves	Global tech startups only	Any Australian founder or small business, at any stage
Status	Dead since 2017	Live and free at getsova.com.au

Compass proved that 34,000 founders wanted a diagnostic tool. Its death proved that diagnosis alone isn't enough. Sova picks up where they left off: diagnosis, plus the frameworks, programs, and guidance to actually act on what you find.

The Need Is Greater Than Ever

The tool was proven. 34,000 founders signed up. The research behind it has only grown stronger over 15 years. And yet nothing replaced it. Meanwhile, Australia's startup ecosystem is under more pressure than ever: early-stage deals down 70%, Series A rounds 34% below the global average, and a structural shortage of growth-stage support.

The research was right in 2011. The need is greater in 2026. The tool is Sova.

Frequently Asked Questions

What was the Startup Genome Project?

The Startup Genome Project was a 2011 research initiative founded by Bjoern Lasse Herrmann, Max Marmer, and Ertan Dogrultan, supported by faculty from Berkeley and Stanford. It analysed over 3,200 high-growth technology startups and found that 74% of failures were caused by premature scaling. The team built Startup Compass, a diagnostic tool used by 34,000 founders, before the company pivoted and was acquired by Sage Group in 2017.

What is premature scaling and why does it cause startup failure?

Premature scaling is when founders grow one area of their business before completing foundational work in another. For example, hiring a sales team before validating product-market fit, or raising capital before understanding unit economics. The Startup Genome research found startups that scaled consistently across all dimensions grew 20 times faster than those that did not.

What happened to Startup Compass?

Startup Compass raised $3 million and rebranded as Compass.co, but pivoted away from startup benchmarking in June 2016 to pursue e-commerce analytics. In March 2017, Sage Group acquired the company for its analytics technology and the diagnostic tool was discontinued. The research arm continued as Startup Genome, which now works with over 160 government agencies across 55 countries.

How is Sova different from Startup Compass?

Compass told founders where they stood through 25 KPIs. Sova goes further: it assesses 9 interconnected business elements across 4 growth stages, then provides specific frameworks to fix what it finds, connects founders to relevant Australian programs and grants, and includes AI-powered guidance contextualised to your assessment results. Compass benchmarked. Sova diagnoses and prescribes.

Why do startups need a diagnostic tool?

Research consistently shows that founders fail because they do not know what they do not know, and they lack a structured way to find out. CB Insights found 38% of startups fail from running out of cash and 35% from no market need. A diagnostic tool reveals these gaps before they become fatal, identifies how weaknesses in one area cascade into others, and points founders to specific actions.

Jane Korneyko

Founder of Sova, a diagnostic for Australian startups. Sova assesses 9 interconnected business elements across 4 growth stages, identifies where a business is exposed, shows how gaps in one area create problems in others, and gives founders evidence-based recommendations and tools matched to where they actually are. Built on 350+ research findings from 80+ published sources and 150+ founder interviews.